{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:12:51Z","timestamp":1782439971400,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by mutations (most frequently in <jats:italic>JAK2<\/jats:italic>, <jats:italic>CALR<\/jats:italic>, or <jats:italic>MPL<\/jats:italic>), burdensome symptoms, splenomegaly, cytopenia, and shortened life expectancy. In addition to other clinical manifestations, patients with MF often develop anemia, which can either be directly related to MF pathogenesis or a result of MF treatment with Janus kinase (JAK) inhibitors, such as ruxolitinib and fedratinib. Although symptoms and clinical manifestations can be similar between the 2 anemia types, only MF-related anemia is prognostic of reduced survival. In this review, I detail treatment and patient management approaches for both types of anemia presentations and provide recommendations for the treatment of MF in the presence of anemia.<\/jats:p>","DOI":"10.1007\/s00277-023-05126-4","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T06:19:59Z","timestamp":1676614799000},"page":"689-698","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["How I manage anemia related to myelofibrosis and its treatment regimens"],"prefix":"10.1007","volume":"102","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"issue":"20","key":"5126_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"25","key":"5126_CR2","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant\u2019Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schonegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379\u20132390","journal-title":"N Engl J Med"},{"issue":"5","key":"5126_CR3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/cancers13050984","volume":"13","author":"A Guijarro-Hernandez","year":"2021","unstructured":"Guijarro-Hernandez A, Vizmanos JL (2021) A broad overview of signaling in Ph-negative classic myeloproliferative neoplasms. Cancers (Basel) 13(5):984. https:\/\/doi.org\/10.3390\/cancers13050984","journal-title":"Cancers (Basel)"},{"key":"5126_CR4","doi-asserted-by":"publisher","first-page":"284706","DOI":"10.1155\/2015\/284706","volume":"2015","author":"HL Geyer","year":"2015","unstructured":"Geyer HL, Dueck AC, Scherber RM, Mesa RA (2015) Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm 2015:284706. https:\/\/doi.org\/10.1155\/2015\/284706","journal-title":"Mediators Inflamm"},{"key":"5126_CR5","doi-asserted-by":"publisher","first-page":"683401","DOI":"10.3389\/fimmu.2021.683401","volume":"12","author":"DAC Fisher","year":"2021","unstructured":"Fisher DAC, Fowles JS, Zhou A, Oh ST (2021) Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front Immunol 12:683401. https:\/\/doi.org\/10.3389\/fimmu.2021.683401","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"5126_CR6","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1182\/blood-2021-151978","volume":"138","author":"LEE Aguirre","year":"2021","unstructured":"Aguirre LEE, Jain AG, Ball S, Al Ali N, Tinsley-Vance SM, Sallman DA, Sweet K, Lancet JE, Padron E, Kuykendall AT, Komrokji RS (2021) Triple-negative myelofibrosis: disease features, response to treatment and outcomes. Blood 138(suppl 1):1494. https:\/\/doi.org\/10.1182\/blood-2021-151978","journal-title":"Blood"},{"issue":"1","key":"5126_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 96(1):145\u2013162. https:\/\/doi.org\/10.1002\/ajh.26050","journal-title":"Am J Hematol"},{"key":"5126_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey. BMC Cancer 16:167. https:\/\/doi.org\/10.1186\/s12885-016-2208-2","journal-title":"BMC Cancer"},{"issue":"3","key":"5126_CR9","doi-asserted-by":"publisher","first-page":"e90299","DOI":"10.1371\/journal.pone.0090299","volume":"9","author":"GL Price","year":"2014","unstructured":"Price GL, Davis KL, Karve S, Pohl G, Walgren RA (2014) Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One 9(3):e90299. https:\/\/doi.org\/10.1371\/journal.pone.0090299","journal-title":"PLoS One"},{"issue":"24","key":"5126_CR10","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Bj\u00f6rkholm M (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 30(24):2995\u20133001. https:\/\/doi.org\/10.1200\/JCO.2012.42.1925","journal-title":"J Clin Oncol"},{"key":"5126_CR11","unstructured":"Badireddy M, Baradhi KM (2022) Chronic anemia. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"issue":"12","key":"5126_CR12","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","volume":"35","author":"F Cervantes","year":"2021","unstructured":"Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK (2021) Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia 35(12):3455\u20133465. https:\/\/doi.org\/10.1038\/s41375-021-01261-x","journal-title":"Leukemia"},{"issue":"1","key":"5126_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H, Comfort-I investigators, (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):55. https:\/\/doi.org\/10.1186\/s13045-017-0417-z","journal-title":"J Hematol Oncol"},{"issue":"12","key":"5126_CR14","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","volume":"101","author":"V Gupta","year":"2016","unstructured":"Gupta V, Harrison C, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, Sun W, Gopalakrishna P, Kantarjian H, Verstovsek S (2016) The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica 101(12):e482\u2013e484. https:\/\/doi.org\/10.3324\/haematol.2016.151449","journal-title":"Haematologica"},{"issue":"25","key":"5126_CR15","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoops L, Gisslinger H, COMFORT-II investigators (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047\u20134053. https:\/\/doi.org\/10.1182\/blood-2013-02-485888","journal-title":"Blood"},{"key":"5126_CR16","unstructured":"National Comprehensive Cancer Network (2022) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myeloproliferative Neoplasms, version 3.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf. Accessed 9 Feb\u00a02023"},{"key":"5126_CR17","unstructured":"JAKAFI\u00ae (ruxolitinib). Full Prescribing Information, Incyte Corporation, Wilmington, DE, USA, 2021"},{"issue":"9","key":"5126_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"issue":"9","key":"5126_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"key":"5126_CR20","doi-asserted-by":"publisher","unstructured":"Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V (2017) Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 10(1):156. https:\/\/doi.org\/10.1186\/s13045-017-0527-7","DOI":"10.1186\/s13045-017-0527-7"},{"key":"5126_CR21","unstructured":"Inrebic\u00ae (fedratinib). Full Prescribing Information, Celgene Corporation, Summit, NJ, USA, 2019"},{"key":"5126_CR22","unstructured":"VONJO\u00ae (pacritinib). Full Prescribing Information, CTI BioPharma Corporation, Seattle, WA, 2022"},{"issue":"5","key":"5126_CR23","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S (2018) Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol 4(5):652\u2013659. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5818","journal-title":"JAMA Oncol"},{"key":"5126_CR24","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.2147\/ott.S267001","volume":"14","author":"JA Waksal","year":"2021","unstructured":"Waksal JA, Tremblay D, Mascarenhas J (2021) Clinical utility of fedratinib in myelofibrosis. Onco Targets Ther 14:4509\u20134521. https:\/\/doi.org\/10.2147\/ott.S267001","journal-title":"Onco Targets Ther"},{"issue":"5","key":"5126_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s11899-021-00651-3","volume":"16","author":"BL Stein","year":"2021","unstructured":"Stein BL (2021) Management of myelofibrosis-associated anemia: focus on standard agents and novel therapeutics in phase 3 clinical trials. Curr Hematol Malig Rep 16(5):483\u2013489. https:\/\/doi.org\/10.1007\/s11899-021-00651-3","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"5126_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12185-019-02717-8","volume":"110","author":"H Yasuda","year":"2019","unstructured":"Yasuda H, Tsutsui M, Ando J, Inano T, Noguchi M, Yahata Y, Tanaka M, Tsukune Y, Masuda A, Shirane S, Misawa K, Gotoh A, Sato E, Aritaka N, Sekiguchi Y, Sugimoto K, Komatsu N (2019) Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients. Int J Hematol 110(5):543\u2013549. https:\/\/doi.org\/10.1007\/s12185-019-02717-8","journal-title":"Int J Hematol"},{"issue":"3","key":"5126_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/ejh.13198","volume":"102","author":"G Birgegard","year":"2019","unstructured":"Birgegard G, Samuelsson J, Ahlstrand E, Ejerblad E, Enevold C, Ghanima W, Hasselbalch H, Nielsen CH, Knutsen H, Pedersen OB, S\u00f8rensen A, Andreasson B (2019) Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN Study Group. Eur J Haematol 102(3):235\u2013240. https:\/\/doi.org\/10.1111\/ejh.13198","journal-title":"Eur J Haematol"},{"key":"5126_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.leukres.2018.01.017","volume":"66","author":"M Lucijanic","year":"2018","unstructured":"Lucijanic M, Prka Z, Pejsa V, Stoos-Veic T, Lucijanic J, Kusec R (2018) Prognostic implications of low transferrin saturation in patients with primary myelofibrosis. Leuk Res 66:89\u201395. https:\/\/doi.org\/10.1016\/j.leukres.2018.01.017","journal-title":"Leuk Res"},{"issue":"4","key":"5126_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/ph11040094","volume":"11","author":"F Busti","year":"2018","unstructured":"Busti F, Marchi G, Ugolini S, Castagna A, Girelli D (2018) Anemia and iron deficiency in cancer patients: role of iron replacement therapy. Pharmaceuticals (Basel) 11(4):94. https:\/\/doi.org\/10.3390\/ph11040094","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"5126_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","volume":"15","author":"HT Chifotides","year":"2022","unstructured":"Chifotides HT, Bose P, Verstovsek S (2022) Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol 15(1):7. https:\/\/doi.org\/10.1186\/s13045-021-01157-4","journal-title":"J Hematol Oncol"},{"issue":"12","key":"5126_CR31","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2217\/fon-2020-1048","volume":"17","author":"S Verstovsek","year":"2021","unstructured":"Verstovsek S, Chen CC, Egyed M, Ellis M, Fox L, Goh YT, Gupta V, Harrison C, Kiladjian JJ, Lazaroiu MC, Mead A, McLornan D, McMullin MF, Oh ST, Perkins A, Platzbecker U, Scheid C, Vannucchi A, Yoon SS, Kowalski MM, Mesa RA (2021) MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol 17(12):1449\u20131459. https:\/\/doi.org\/10.2217\/fon-2020-1048","journal-title":"Future Oncol"},{"issue":"Supplement 1","key":"5126_CR32","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1182\/blood-2022-169210","volume":"140","author":"SR Mohan","year":"2022","unstructured":"Mohan SR, Oh ST, Ali H, Hunter AM, Palandri F, Lamothe B, Cui Y, Seguy F, McBride A, Savona MR, Kiladjian J-J, Verstovsek S (2022) A phase 1\/2 study of INCB000928 as monotherapy or combined with ruxolitinib (RUX) in patients (Pts) with anemia due to myelofibrosis (MF). Blood 140(suppl 1):3943\u20133944. https:\/\/doi.org\/10.1182\/blood-2022-169210","journal-title":"Blood"},{"issue":"12","key":"5126_CR33","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00277-008-0516-6","volume":"87","author":"LI Kornblihtt","year":"2008","unstructured":"Kornblihtt LI, Vassalllu PS, Heller PG, Lago NR, Alvarez CL, Molinas FC (2008) Primary myelofibrosis in a patient who developed primary biliary cirrhosis, autoimmune hemolytic anemia and fibrillary glomerulonephritis. Ann Hematol 87(12):1019\u20131020. https:\/\/doi.org\/10.1007\/s00277-008-0516-6","journal-title":"Ann Hematol"},{"key":"5126_CR34","volume-title":"Iron deficiency anemia","author":"MJ Warner","year":"2021","unstructured":"Warner MJ, Kamran MT (2021) Iron deficiency anemia. StatPearls Publishing, Treasure Island, FL"},{"issue":"5","key":"5126_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1586\/17474086.2016.1154452","volume":"9","author":"F Cervantes","year":"2016","unstructured":"Cervantes F, Correa JG, Hernandez-Boluda JC (2016) Alleviating anemia and thrombocytopenia in myelofibrosis patients. Expert Rev Hematol 9(5):489\u2013496. https:\/\/doi.org\/10.1586\/17474086.2016.1154452","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"5126_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1017\/S0007114518001356","volume":"120","author":"EJ Laird","year":"2018","unstructured":"Laird EJ, O\u2019Halloran AM, Carey D, O\u2019Connor D, Kenny RA, Molloy AM (2018) Voluntary fortification is ineffective to maintain the vitamin B12 and folate status of older Irish adults: evidence from the Irish Longitudinal Study on Ageing (TILDA). Br J Nutr 120(1):111\u2013120. https:\/\/doi.org\/10.1017\/S0007114518001356","journal-title":"Br J Nutr"},{"issue":"4","key":"5126_CR37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ejh.12846","volume":"98","author":"JC Hern\u00e1ndez-Boluda","year":"2017","unstructured":"Hern\u00e1ndez-Boluda JC, Correa JG, Garc\u00eda-Delgado R, Mart\u00ednez-L\u00f3pez J, Alvarez-Larr\u00e1n A, Fox ML, Garc\u00eda-Guti\u00e9rrez V, P\u00e9rez-Encinas M, Ferrer-Mar\u00edn F, Mata-V\u00e1zquez MI, Raya JM, Estrada N, Garc\u00eda S, Kerguelen A, Dur\u00e1n MA, Albors M, Cervantes F (2017) Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. Eur J Haematol 98(4):407\u2013414. https:\/\/doi.org\/10.1111\/ejh.12846","journal-title":"Eur J Haematol"},{"issue":"5","key":"5126_CR38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.15450","volume":"182","author":"E Cris\u00e0","year":"2018","unstructured":"Cris\u00e0 E, Cilloni D, Elli EM, Martinelli V, Palumbo GA, Pugliese N, Beggiato E, Frairia C, Cerrano M, Lanzarone G, Marchetti M, Mezzabotta M, Boccadoro M, Ferrero D (2018) The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. Br J Haematol 182(5):701\u2013704. https:\/\/doi.org\/10.1111\/bjh.15450","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"5126_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2019-122546","volume":"134","author":"AT Gerds","year":"2019","unstructured":"Gerds AT, Vannucchi AM, Passamonti F, Kremyanskaya M, Gotlib JR, Palmer JM, McCaul K, Ribrag V, Mead AJ, Harrison CN, Mesa RA, Kiladjian J-J, Barosi G, Gale RP, Laadem A, Pariseau J, Gerike T, Zhang J, Linde PG, Reynolds JG, Verstovsek S (2019) A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. Blood 134(suppl 1):557. https:\/\/doi.org\/10.1182\/blood-2019-122546","journal-title":"Blood"},{"issue":"suppl 1","key":"5126_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2020-137232","volume":"136","author":"RS Komrokji","year":"2020","unstructured":"Komrokji RS, Platzbecker U, Fenaux P, Garcia-Manero G, Mufti GJ, Santini V, Diez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, Zeidan AM, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Sinsimer D, Backstrom JT, Verma A (2020) Efficacy and safety of luspatercept treatment in patients with myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T): a retrospective analysis from the Medalist study. Blood 136(suppl 1):13\u201315. https:\/\/doi.org\/10.1182\/blood-2020-137232","journal-title":"Blood"},{"issue":"11","key":"5126_CR41","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","volume":"94","author":"F Cervantes","year":"2015","unstructured":"Cervantes F, Isola IM, Alvarez-Larr\u00e1n A, Hern\u00e1ndez-Boluda JC, Correa JG, Pereira A (2015) Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol 94(11):1791\u20131796. https:\/\/doi.org\/10.1007\/s00277-015-2435-7","journal-title":"Ann Hematol"},{"issue":"12","key":"5126_CR42","doi-asserted-by":"publisher","first-page":"e956","DOI":"10.1016\/j.clml.2020.07.006","volume":"20","author":"F Castillo-Tokumori","year":"2020","unstructured":"Castillo-Tokumori F, Talati C, Al Ali N, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT (2020) Retrospective analysis of the clinical use and benefit of lenalidomide and thalidomide in myelofibrosis. Clin Lymphoma Myeloma Leuk 20(12):e956\u2013e960. https:\/\/doi.org\/10.1016\/j.clml.2020.07.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"5126_CR43","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","volume":"22","author":"M Marchetti","year":"2004","unstructured":"Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory JL, Ilariucci F, Volpe A, Bordessoule D, Grossi A, Le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B (2004) Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 22(3):424\u2013431. https:\/\/doi.org\/10.1200\/JCO.2004.08.160","journal-title":"J Clin Oncol"},{"issue":"8","key":"5126_CR44","first-page":"1027","volume":"91","author":"JF Abgrall","year":"2006","unstructured":"Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L, Boyer F, Casassus P, Slama B, Berthou C, Rodon P, Leporrier M, Villemagne B, Himberlin C, Ghomari K, Larosa F, Rollot F, Dugay J, Allard C, Maigre M, Isnard F, Zerbib R, Cauvin JM, Groupe Ouest-Est Leucemies et Maladies\u00a0du Sang (GOELAMS) (2006) Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 91(8):1027\u20131032","journal-title":"Haematologica"},{"issue":"5","key":"5126_CR45","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/leu.2017.2","volume":"31","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP (2017) A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia 31(5):1252. https:\/\/doi.org\/10.1038\/leu.2017.2","journal-title":"Leukemia"},{"issue":"4","key":"5126_CR46","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/hon.3026","volume":"40","author":"S Qu","year":"2022","unstructured":"Qu S, Xu Z, Qin T, Li B, Pan L, Chen J, Yan X, Wu J, Zhang Y, Zhang P, Gale RP, Xiao Z (2022) Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: results of a pilot study. Hematol Oncol 40(4):787\u2013795. https:\/\/doi.org\/10.1002\/hon.3026","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"5126_CR47","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1182\/blood-2021-150894","volume":"138","author":"S Verstovsek","year":"2021","unstructured":"Verstovsek S, Kiladjian J-J, Vannucchi AM, Mesa RA, Scherber R, Hamer-Maansson JE, Harrison CN (2021) Does early intervention in myelofibrosis impact outcomes? A pooled analysis of the COMFORT I and II studies. Blood 138(suppl 1):1505. https:\/\/doi.org\/10.1182\/blood-2021-150894","journal-title":"Blood"},{"issue":"4","key":"5126_CR48","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1080\/10428194.2020.1845334","volume":"62","author":"V Gupta","year":"2021","unstructured":"Gupta V, Griesshammer M, Martino B, Foltz L, Tavares R, Al-Ali HK, Giraldo P, Guglielmelli P, Lomaia E, Bouard C, Paley C, Tiwari R, Zor E, Raanani P (2021) Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leuk Lymphoma 62(4):918\u2013926. https:\/\/doi.org\/10.1080\/10428194.2020.1845334","journal-title":"Leuk Lymphoma"},{"issue":"45","key":"5126_CR49","doi-asserted-by":"publisher","first-page":"79073","DOI":"10.18632\/oncotarget.18674","volume":"8","author":"F Palandri","year":"2017","unstructured":"Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D\u2019Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M (2017) Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget 8(45):79073\u201379086. https:\/\/doi.org\/10.18632\/oncotarget.18674","journal-title":"Oncotarget"},{"issue":"5","key":"5126_CR50","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A (2015) Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 1(5):643\u2013651. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1590","journal-title":"JAMA Oncol"},{"issue":"16 suppl","key":"5126_CR51","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.1200\/JCO.2022.40.16_suppl.7002","volume":"40","author":"RA Mesa","year":"2022","unstructured":"Mesa RA, Gerds AT, Vannucchi A, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan DP, Perkins A, Yoon S-S, Gupta V, Kiladjian J-J, Donahue R, Kawashima J, Verstovsek S (2022) MOMENTUM: phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. J Clin Oncol 40(16 suppl):7002\u20137002. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7002","journal-title":"J Clin Oncol"},{"key":"5126_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.leukres.2017.06.005","volume":"60","author":"K Gowin","year":"2017","unstructured":"Gowin K, Kosiorek H, Dueck A, Mascarenhas J, Hoffman R, Reeder C, Camoriano J, Tibes R, Gano K, Palmer J, Mesa R (2017) Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leuk Res 60:31\u201335","journal-title":"Leuk Res"},{"issue":"Supplement 1","key":"5126_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2020-137265","volume":"136","author":"AT Gerds","year":"2020","unstructured":"Gerds AT, Vannucchi AM, Passamonti F, Kremyanskaya M, Gotlib J, Palmer JM, McCaul K, Ribrag V, Mead AJ, Harrison C, Mesa R, Kiladjian J-J, Barosi G, Gerike TG, Shetty JK, Pariseau J, Miranda G, Schwickart M, Giuseppi AC, Zhang J, Backstrom JT, Verstovsek S (2020) Duration of response to luspatercept in patients (pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF) - updated data from the phase 2 ACE-536-MF-001 study. Blood 136(suppl 1):47\u201348. https:\/\/doi.org\/10.1182\/blood-2020-137265","journal-title":"Blood"},{"issue":"suppl 1","key":"5126_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1182\/blood.V130.Suppl_1.255.255","volume":"130","author":"P Bose","year":"2017","unstructured":"Bose P, Daver N, Pemmaraju N, Jabbour EJ, Estrov Z, Pike A, Huynh-Lu J, Nguyen-Cao M, Wang X, Zhou L, Pierce S, Kantarjian HM, Verstovsek S (2017) Sotatercept (ACE-011) alone and in combination with ruxolitinib in patients (pts) with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and anemia. Blood 130(suppl 1):255. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.255.255","journal-title":"Blood"},{"issue":"suppl 1","key":"5126_CR55","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood-2019-127661","volume":"134","author":"RK Rampal","year":"2019","unstructured":"Rampal RK, Verstovsek S, Devlin SM, King AC, Stein EM, Pemmaraju N, Mauro MJ, Kadia TM, Montalban-Bravo G, Alvarez K, Ard N, Goodman T, Taylor B, Bose P (2019) Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: a phase II study. Blood 134(suppl 1):4163. https:\/\/doi.org\/10.1182\/blood-2019-127661","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05126-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05126-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05126-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T21:27:46Z","timestamp":1678397266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05126-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5126"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05126-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"7 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SV received research support from AstraZeneca, Blueprints Medicines Corp., Celgene, CTI BioPharma Corp., Genentech, Gilead, Incyte, ItalPharma, Novartis, NS Pharma, PharmaEssentia, Promedior, Protagonist Therapeutics, Roche, and Sierra Oncology; and is a paid consultant for Celgene, Incyte, Novartis, and Sierra Oncology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}